We have documented that the Rous sarcoma virus (RSV) internal enhancer functions in the nontransformed Baby Hamster Kidney (BHK) cell line. The sequences within this region were assayed for their ability to bind to specific factors present in BHK nuclear extracts using the gel retardation assay and DNAse I footprinting. At least two sequences within the internal enhancer which can specifically bind nuclear factors in vitro have been identified. These regions are located between nucleotides 813-850 and 856-877. These sites map within the overall region of the internal enhancer which has been shown to be essential for enhancer activity and within the specific region which can function as an orientation independent enhancer. Using the DNase I footprinting and binding data to design an oligonucleotide , we have demonstrated that an oligonucleotide extending from nucleotides 804-877 will substitute efficiently as an enhancer. We also demonstrate that the SV40 enhancer does not compete for the factors which bind to the RSV internal enhancer, whereas an oligonucleotide to the binding site for EFII in the LTR can compete for factor binding to the internal enhancer.
INTRODUCTION
The long terminal repeats (LTRs) of retroviruses have long been considered to contain all the cis-acting elements required for retroviral gene transcription (1,2,3,4,5). However, several recent lines of evidence suggest that other areas within the actual coding region of the viral genome may play some regulatory role (6, 7, 8, 9) . A region of the gag gene between nucleotides 630 and 1149 of the Rous sarcoma virus (RSV) has been found to be required in cis for the efficient transformation of NIH-3T3 cells (9) . This same region (in RSV, RAV-0, and FSV) has also been demonstrated to possess an enhancer activity (6) . This enhancer functions with some orientation dependence and can also augment the activity of the previously identified enhancer located within the LTR.
The internal enhancer region, as well as the LTR enhancer, has also been found to contain a prominent DNAse I hypersensitive site within the provirus in mouse cells (10) and the protein pellet was collected at 100,000xg for 30 minutes. The pellet was then redissolved in 10 mM Hepes, pH 8.0, 300 mM NaCl, 5 mM 2-mercaptoethanol, 50% glycerol and dialyzed overnight against the same buffer.
Protein was quantitated according to the method of Bradford (26) .
Partial Purification of Extracts
The 0.3-0.5M NaCl nuclear extracts were diluted to 250mM NaCl, the insoluble material was pelleted at 20,000xg and the supernatant was applied to hydroxyapatite (Biorad) at a concentration of 1 mg protein per ml resin. The specific binding factors were eluted with 30 mH sodium phosphate, 2M NaCl, 5% glycerol, 0.005% NP40 and 5mM P-mercaptoethanol, pH 7.7. The protein peak was then desalted on a Sephadex G-25 column in 10 mM Hepes, pH 8.0, 25OmM NaCl, 5% glycerol, 0.01% NP40 and 5mM 3-mercaptoethanol. The protein peak was reapplied to hydroxyapatite at 9 mg of protein per ml of resin and washed with 90mM sodium phosphate, pH 7.7, 50% glycerol, 0.01% NP40mM and 5mM Pmercaptoethanol. Specific binding factors were eluted with the same buffer containing 500 mM sodium phosphate, pH 7.7. The protein peak was then desalted on a Sephadex G-25 column containing lOmM Hepes, pH 8.0, 250mH NaCl, 50% glycerol, 0.1 mM EDTA, 5mM dithiothreitol and 0.01% NP40.
Plasmid constructions.
The plasmid, pTZ-RSVIEN, was constructed by ligating the Xhol-Bcll (nucleotides 622-1143) fragment from pSRA-2 (27) , which contained the previously described internal enhancer, into the Sail and Bell sites of pTZ18R (United States Biochemical Corp.). The plasmids used for transfection assays were constructed basically as described by Arrigo et al., except that the enhancer fragment was digested out of the polylinker of pTZ-RSVIEN with EcoRI
and Hindlll, blunt-ended with the Klenow fragment (PL Biochemicals) and cloned into either the blunt-ended Ndel or BamHI site of pSVl (28) . All plasmids were prepared by alkaline lysis procedure and centrifugation to equilibrium in CsCl and ethidium bromide.
Preparation of Restriction Fragments.
Restriction fragments were purified by electrophoresis in 8% acrylamide gels. The running buffer was TBE. The gals were then stained with 0.5 mg/ml ethidium bromide for 10 minutes and the appropriate band was excised and electroeluted in 4.5 mM Tris, 4.5 mM boric acid and 0.13 mM EDTA which contained 0.1% NP40. Fragments were ethanol precipitated before use. Fragments were labelled with either the Klenow fragment or by phosphatasing with bacterial alkaline phosphatase (Bethesda Research Laboratories) and then labeling with y-32p A T P and T4 polynucleotide kinase (New England Biolabs).
Oligonucleotide Preparation.
Oligonucleotides were synthesized on an Applied Biosystems DNA synthesizer by the Diabetes Core Facility at Vanderbilt University.
Oligonucleotides were dissolved in 90% tormamide and electrophoresed on a 20% acrylamide, 7H urea gel, located by ethidium bromide staining and electroeluted and recovered as described above. The single strands were then mixed in equlmolar amounts at a concentration of 5 mg/ml and heated to 88°C.
This was then allowed to slowly cool to room temperature at an average rate of about 4°C/hour.
Gel Retardation Assays.
Binding reactions were carried out under the following conditions; 10 mM Hepes, pH 8.0, 120 mM NaCl, 3 mM MgCl2, 17* glycerol, 0.0H NP40, 0.2 mg/ml poly(dI:dC).poly(dI:dC) (Pharmacia). Binding reactions were in 20 ul and contained 0.2 ng of labelled probe and the specified amount of nuclear extract. Binding was allowed to proceed for 10-15 minutes at 23°C and then loaded directly onto a 4% acrylamide gel and analyzed as previously described (16) .
DNAse I Footprinting Reactions.
Hindlll-Styl fragments labelled at the Styl site by either polynucleotide kinase or the Klenow fragment, were incubated with increasing amounts of partially purified nuclear extracts for 15 minutes at 23°C. DNAse I was then added to a concentration of 2 ug/ml and allowed to react for 1 minute at 23"C.
The reactions were stopped by adding sarkosyl to IX, EDTA to 10 mM and proteinase K to 0.2 mg/ml. The samples were incubated at 65°C for 1 hour, ethanol precipitated and analyzed on an 8% acrylamide, 7 M urea, 20% formamide sequencing gel alongside the reaction products of the purine specific cleavage as previously described (29) . 
CAT Assays
Preparation of cell extracts and CAT assays were performed according to Gorman et al (3, 28) . Twenty ul of extract and a 30 minute incubation at 37°C were used per assay. The autoradiogram of the TLC plate was used as a template to cut out the regions containing acetylated and unmodified chloramphenicol and quantitated by scintillation counting. Extracts of cells transfected with salmon sperm DNA alone were assayed to determine the background level of CAT activity and was subtracted for calculating the amount of chloramphenicol modified.
RESULTS
The Rous Sarcoma Virus Internal Enhancer also Functions in Hamster Cells.
BHK cells were used as a model system for analysis and identification of proteins which bind to the the recently identified internal enhancer of the RSV. This cell line was chosen since we have had an ongoing interest in the chromatin structure of actively transcribed genes and the integrated RSV provirus in the transformed cell line, SR3/la is an ideal candidate for such a study (22) .
We have determined, in agreement with previous observations, that the sequence between Xhol and Ecll (nucleotide 622-1149) of the the Schmidt-Ruppin A strain, which functions as an enhancer in CV-1 cells (9), chick embryo fibroblasts and NIH 3T3 cells (6) , also functions as an enhancer in hamster Figure 1 were incubated with the crude nuclear extracts in the presence of increasing amounts of competitor fragments and analyzed using the gel retardation assay. The labelled fragment which was used is shown and the competitor and the molar excess used are also shown. The competitors used are N-P, Narl-PvuII; P-S, PvuII-Styl; S-E, Styl-EcoRI from the internal enhancer and pBR, the BamHI-Sall fragment of pBR322.
this figure indicates that there is no binding which might be located near the Styl site which was being destroyed by using this as a fragment boundary.
Binding Activities are Sequence Specific.
Each of the fragments capable of binding protein (as documented in figure   1 ) was then tested to determine if the binding activities were specific. Figure 2 demonstrates that the three fragments (Narl-PvuII, PvuII-Styl, and
Styl-EcoRI) which were able to bind factors in the nuclear extracts also show specific competition. The labelled Narl-PvuII fragment was incubated with a nuclear extract along with a 0, 10, 50 or 100-fold molar excess of either the unlabelled Narl-PvuII fragment or an equivalent molar excess of a pBR322
BamHI-Sall 275 bp fragment. A significant fraction of the binding is removed by a 10 fold molar excess of the specific competitor. In contrast, no competition is seen even at a fifty-fold molar excess with the pBR322 fragment. Restriction digested total vector DNA also shows no ability to compete for binding (data not shown), indicating that the lack of competition is not confined to this particular fragment of pBR322. As can also be seen in figure 2 , binding to PvuII-Styl is specifically and efficiently competed by the corresponding unlabelled fragment and is not competed by the pBR322 275 bp fragment. 
Competition for Binding Using other Retroviral Fragments and the SV40
Enhancer.
The SV40 enhancer was tested as a competitor for the RSV internal enhancer binding proteins. The SV40 fragment used for the competitor assays extended from PvuII-Bgll (nucleotides 5235-270) of the SV40 strain WT800 (4).
The fragment located between the LTR and the internal enhancer region was also included in the competition as a control. This fragment extended from BstEII- Figure 4 . Nuclear Proteins Also Bind to the Oligonucleotides. The oligonucleotides which were used as competitors for figure 3 were labelled and the duplex form gel purified. These were then incubated with the indicated increasing amounts of the crude nuclear extracts and analyzed using the gel retardation assay.
BamHI (nucleotides 103-524). Figure 5A demonstrates the results of these competitions. The SV40 fragment cannot effectively compete for the binding sites which are located between Hindlll-Styl. The other internal fragment which was tested (BstEII-BamHI), showed a small amount of competition. The exact nature of this competition is unknown at this time, although little sequence homology is evident between these regions.
We have used fragments from the plasmid, pRSV-LTR (16) itself. Recent work with more highly purified proteins has indicated that the binding activity can be resolved into two components each of which leads to the formation of a specific complex, which would exclude the third possibility. Discrimination between the first two possibilities should be possible after further purification of the separate factors. As purification proceeds we will also be able to determine the relationship of the factors which recognize IES1 and IES2 to those which recognize EFII in the LTR.
Finally, the organization of this enhancer element resembles that of other enhancer elements, in that multiple binding sites reported here resemble the multiple block, organization of other enhancers (25, 36, 37) . If IES1 and IES2 are indeed repeated sequence motifs, the enhancer may resemble mutated enhancers which have been produced by duplicating any one of the blocks (25,36,37 and reference therein). We are currently determining the minimum sequence requirements for this enhancer and if a repetition of one of these blocks will generate a fully active enhancer.
